Peptide Research

Epitalon is a synthetic tetrapeptide based on the naturally occurring peptide epithalamin, which is extracted from the pineal gland. Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, epitalon is the most extensively studied of the Khavinson peptide bioregulators. Its primary mechanism of action involves activation of telomerase, the enzyme responsible for maintaining telomere length at chromosome ends.

Telomeres shorten with each cell division, and this progressive shortening is considered a key hallmark of cellular aging. When telomeres become critically short, cells enter senescence or undergo apoptosis. Khavinson and colleagues demonstrated that epitalon can activate telomerase in human somatic cells, leading to elongation of telomeres and extension of cellular lifespan beyond the Hayflick limit. This was shown in human fetal fibroblast cultures where epitalon-treated cells underwent significantly more population doublings than controls.

Epitalon also influences melatonin production. As a pineal bioregulator, it has been shown to restore the nocturnal melatonin peak in aged primates, which normally declines with age. This melatonin-related activity provides a secondary mechanism through which epitalon may affect aging processes, given melatonin's roles as an antioxidant and circadian regulator.

Thymalin is a polypeptide preparation originally isolated from calf thymus glands, developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. It consists of a complex of small peptides that have been studied extensively in Russian clinical practice for immunomodulatory and geroprotective properties. The primary bioactive component is believed to be the dipeptide Glu-Trp, which has been studied independently as a thymic bioregulator.

The mechanism of action involves modulation of T-cell maturation and differentiation pathways. The thymus is the primary organ responsible for T-cell development and education, but it undergoes progressive involution (shrinkage) with age, leading to diminished output of naive T-cells and gradual immune decline (immunosenescence). Thymalin research focuses on its ability to partially restore thymic function and improve T-cell populations.

Khavinson et al. conducted a landmark 15-year longitudinal study in elderly patients (60-80 years) who received annual cycles of thymalin combined with epithalamin (the precursor of synthetic epitalon). The treated group showed significantly improved immune function, reduced incidence of acute respiratory infections, ischemic heart disease, hypertension, osteoporosis, and osteoarthritis, and remarkably, a 2-fold reduction in mortality rate compared to controls. While these results are striking, the study was conducted in Russia and may not have been subject to the same peer review standards as Western clinical trials.